pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)
MSD Merck Sharp
Merck Sharp and Dohme
Merck Sharp and is a pharma organization headquartered in EU. Primary therapeutic focus areas include Atherosclerosis, Non-small Cell Lung Cancer (NSCLC), Hypercholesterolemia, HIV infection, Acute and chronic Pain. Nova
Company details
- Status
- Public
- HQ
- WERFTESTRASSE 4, Lucerne, 6005, ch
- Employees
- 61
- Programs
- 217
- Drugs
- 180
- Patents
- 0
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Phase 1 · other · Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).
Effect of Renal Impairment on Enpatoran Pharmacokinetics for Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM). is a Phase 1 program (other) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Internal code MS200569_0051
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Merck Sharp and Dohme
- Phase
- Phase 1
- Modality
- other
- Indication
- Healthy volunteers and patients with renal impairment; Intended indication: autoimmune diseases; systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE), as well as dermatomyositis (DM) and polymyositis (PM).
- Status
- active
- Trials
- 1